Finance

Lists
AGIO:NASDAQ
Agios Pharmaceuticals Inc
29,56 $
-1,96%
(-0,59) 1D
17 նոյ, 13:47:57 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGIO...
Open
30,09 $
High
30,38 $
Low
28,94 $
Mkt. cap
1,77 մլրդ
Avg. vol.
1,23 մլն
Volume
244,21 հզր
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 մլն
No. of employees
540
Open
30,09 $
High
30,38 $
Low
28,94 $
Mkt. cap
1,77 մլրդ
Avg. vol.
1,23 մլն
Volume
244,21 հզր
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-6,32 $
Beta
0,66
Shares outstanding
59,81 մլն
No. of employees
540
News stories
From web sources and news partners
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
CEO-
Employees540
Founded2008
Headquarters-
SectorHealth Care
Industry-
Websiteagios.com
Analyst ratings
Based on 6 analysts giving stock ratings to AGIO in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AGIO in the last 3 months.
Highest
Current 29,56 $
62,00 $ (+109,74%)
Average
45,80 $ (+54,94%)
Lowest
32,00 $ (+8,25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luca Issi
RBC Capital
Hold
Maintained
32,00 $
+8,3%
11/05/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
48,00 $
+62,4%
11/06/2026
Douglas Tsao
H.C. Wainwright
Buy
Maintained
62,00 $
+109,7%
11/06/2026
Gregory Renza
Truist Financial
Buy
Maintained
35,00 $
+18,4%
11/06/2026
Tessa Romero
J.P. Morgan
Hold
Maintained
-
-
10/31/2026
Samantha Semenkow
Citi
Buy
Maintained
52,00 $
+75,9%
10/28/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/03/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
55,00 $
+86,1%
07/30/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
32,00 $
+8,3%
07/21/2026
Andrew Berens
Leerink Partners
Buy
Maintained
-
-
07/07/2026
Last report
05 նոյ, 2026 թ.
Fiscal period
Q3 2026
-1,09 $ / -1,23 $
+11,38%beat
Revenue / Est. (USD)
55,38 մլն / 51,60 մլն
+7,33%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
19,97 մլն
20,75 մլն
44,74 մլն
55,38 մլն
Cost of goods sold
89,94 մլն
82,47 մլն
103,75 մլն
76,01 մլն
Cost of revenue
89,94 մլն
82,47 մլն
103,75 մլն
76,01 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
51,61 մլն
48,30 մլն
51,55 մլն
56,53 մլն
Operating expense
51,61 մլն
48,30 մլն
51,55 մլն
56,53 մլն
Total operating expenses
141,54 մլն
130,77 մլն
155,30 մլն
132,54 մլն
Operating income
-121,58 մլն
-110,02 մլն
-110,55 մլն
-77,16 մլն
Other non operating income
113,00 հզր
119,00 հզր
119,00 հզր
3,24 մլն
EBT including unusual items
-109,06 մլն
-99,11 մլն
-100,70 մլն
-65,04 մլն
EBT excluding unusual items
-109,06 մլն
-99,11 մլն
-100,70 մլն
-65,04 մլն
Income tax expense
-1,02 մլն
-
-
-
Effective tax rate
0,93%
-
-
-
Other operating expenses
-
-
-
-
Net income
-108,04 մլն
-99,11 մլն
-100,70 մլն
-65,04 մլն
Net profit margin
-541,09%
-477,74%
-225,06%
-117,44%
Earnings per share
-1,85
-1,69
-1,69
-1,09
Interest and investment income
12,41 մլն
10,80 մլն
9,73 մլն
8,88 մլն
Interest expense
-
-
-
-
Net interest expenses
12,41 մլն
10,80 մլն
9,73 մլն
8,88 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-120,31 մլն
-108,66 մլն
-109,20 մլն
-75,71 մլն
Gain or loss from assets sale
-299,00 հզր
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps